Based on the AREDS and AREDS2 clinical studies

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

The Most Studied Eye
Vitamin Brand

New! 10 Year Follow-On Study Results are Here. Read More

We share a goal: To help reduce the risk of progression to advanced AMD and its associated vision loss. That’s why we’ve worked with the National Eye Institute (NEI) to develop the formula recommended by the NEI to help reduce the risk of progression in patients with moderate to advanced AMD.

The AREDS Studies

How We Help You Help Your Patients

Our Formula

PreserVision® contains the exact levels of nutrients recommended by the NEI to help reduce the risk of moderate to advanced AMD progression.

Over 20 Years of Clinical Science

PreserVision is the most studied eye vitamin brand.* In fact, it was the brand used in the last 5 years of the NEI's 10 year follow-on study.

*Based on AREDS and AREDS2 clinical studies

Resources for Your Patients

Call our hotline to request free patient samples and literature.
You can also learn more on our patient education site, SightMatters.

The Science

The NEI continues to study AREDS2 supplements in patients with moderate-to-advanced AMD. In 2022, the NEI published the results of the AREDS2 10 year follow-on study, contributing to over two decades of demonstrated data.

The AREDS Studies

The Supplement

PreserVision® contains the exact levels of nutrients recommended by the NEI to help reduce the risk of moderate-to-advanced AMD progression. In fact, the NEI used PreserVision® in the last 5 years of its 10 year follow-on study.

Our Formula
Top Reasons Why ECPs 
Recommend PreserVision®

(We surveyed 200 optometrists and ophthalmologists)

1

Contains the nutrient formula recommended by the NEI to help lower the risk of moderate to advanced AMD progression.1

2

Matches the exact levels of key nutrients recommended by the NEI.
PreserVision is the most studied eye vitamin brand.2

3

No side effects or tolerability issues reported in the AREDS trials.3 Published NEI AREDS2 data indicates no significant safety concerns and tolerability issues for the AREDS2 formula at 10 years.

  1. Over 10 years, compared to placebo
  2. Based on AREDS and AREDS2 clinical studies
  3. Two doses per day, every day

Helping You Help Your Patients

How many minutes can you give to each AMD patient? Our patient education website and materials can help you offer maximum support.

For Your Patients

Text Size:A−A+